Michael Barbella, Managing Editor01.09.24
Rockwell Medical Inc. has named Jesse Neri as senior vice president, Finance. He will oversee all aspects of Rockwell Medical's finance organization.
"Jesse's extensive experience leading finance organizations within revenue-generating, growth-oriented healthcare businesses will be valuable to Rockwell Medical as we contemplate various avenues of expansion and growth," Rockwell Medical President/CEO Mark Strobeck, Ph.D., said. "Additionally, Jesse's expertise will enhance our ability to continue strengthening our financial and operating infrastructure while advancing our ability to meet our strategic objectives."
Neri has more than 20 years' experience leading finance functions at both public and private companies. Prior to joining Rockwell Medical, he was the head of finance at Hemavant Sciences, a clinical stage biopharmaceutical company developing therapeutics to improve patients' lives with blood disorders and hematological malignancies. Neri was senior vice president of Finance at Zyla Life Sciences, a public pharmaceutical company with annual revenue of $80 million. As a member of the senior management team, Neri was responsible for all aspects of its finance organization including SEC reporting, audit, controllership, and strategic planning. While at Zyla, he played a pivotal role in multiple product acquisitions, financings, commercial product launches and regulatory approvals, along with Zyla's acquisition by Assertio Therapeutics in May 2020. Prior to Zyla, Neri was vice president of Financial Planning and Analysis at Symphony Health Solutions, a private equity-backed market research company with revenues of more than $200 million.
Neri earned a B.S. in business administration and finance from Villanova University and an M.B.A. from Drexel University LeBow School of Business.
“I am thrilled to be joining Rockwell Medical as its new head of finance at such an exciting time in the Company's history," Neri said. "Rockwell Medical continues to improve its balance sheet and expand its leadership position in the renal healthcare space. I am excited to be part of a team that is focused on innovative, long-term growth strategies that have the potential to positively impact patients and shareholders around the globe."
The Rockwell Board's Compensation Committee approved the grant of stock options to purchase 75,000 shares of the company’s common stock to Neri. The Inducement Grant has been granted outside of the company’s 2018 Long Term Incentive Plan but remains subject to the terms and conditions of such Plan. The Inducement Grant will vest 25% on each of the first four anniversaries of the Grant Date until fully vested, subject to Neri’s continued employment through the applicable vesting dates.
Rockwell Medical Inc. develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. Rockwell Medical provides dialysis clinics and the patients they serve with products supported by customer service. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the company to deliver value to the healthcare system and provide a positive impact on hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States and has the vision of becoming the leading global supplier of hemodialysis concentrates.
"Jesse's extensive experience leading finance organizations within revenue-generating, growth-oriented healthcare businesses will be valuable to Rockwell Medical as we contemplate various avenues of expansion and growth," Rockwell Medical President/CEO Mark Strobeck, Ph.D., said. "Additionally, Jesse's expertise will enhance our ability to continue strengthening our financial and operating infrastructure while advancing our ability to meet our strategic objectives."
Neri has more than 20 years' experience leading finance functions at both public and private companies. Prior to joining Rockwell Medical, he was the head of finance at Hemavant Sciences, a clinical stage biopharmaceutical company developing therapeutics to improve patients' lives with blood disorders and hematological malignancies. Neri was senior vice president of Finance at Zyla Life Sciences, a public pharmaceutical company with annual revenue of $80 million. As a member of the senior management team, Neri was responsible for all aspects of its finance organization including SEC reporting, audit, controllership, and strategic planning. While at Zyla, he played a pivotal role in multiple product acquisitions, financings, commercial product launches and regulatory approvals, along with Zyla's acquisition by Assertio Therapeutics in May 2020. Prior to Zyla, Neri was vice president of Financial Planning and Analysis at Symphony Health Solutions, a private equity-backed market research company with revenues of more than $200 million.
Neri earned a B.S. in business administration and finance from Villanova University and an M.B.A. from Drexel University LeBow School of Business.
“I am thrilled to be joining Rockwell Medical as its new head of finance at such an exciting time in the Company's history," Neri said. "Rockwell Medical continues to improve its balance sheet and expand its leadership position in the renal healthcare space. I am excited to be part of a team that is focused on innovative, long-term growth strategies that have the potential to positively impact patients and shareholders around the globe."
The Rockwell Board's Compensation Committee approved the grant of stock options to purchase 75,000 shares of the company’s common stock to Neri. The Inducement Grant has been granted outside of the company’s 2018 Long Term Incentive Plan but remains subject to the terms and conditions of such Plan. The Inducement Grant will vest 25% on each of the first four anniversaries of the Grant Date until fully vested, subject to Neri’s continued employment through the applicable vesting dates.
Rockwell Medical Inc. develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. Rockwell Medical provides dialysis clinics and the patients they serve with products supported by customer service. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the company to deliver value to the healthcare system and provide a positive impact on hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease. Rockwell Medical is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States and has the vision of becoming the leading global supplier of hemodialysis concentrates.